rifamycin sodium · Cosmo Technologies · NDA 210910
Aemcolo
Earliest generic entry, as listed
16 Nov 2028
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by exclusivity: GAIN.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 1 unexpired
| GAIN | qualified infectious disease product | 16 Nov 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210910 · 001 · RLD · discontinued | tablet, delayed release, oral | EQ 194MG BASE | 16 Nov 2028 |
Expired or delisted (1)
- NCE · 16 Nov 2023